The combined use of a CDK4/6 inhibitor with endocrine therapy yielded a 9.4-month median OS benefit among patients.
The agency is set to make a decision on the investigational antibody drug conjugate by the first quarter of 2020.
CancerNetwork® spoke with Dr. Sara Hurvitz, associate professor of medicine at the University of California, Los Angeles, about therapy options for breast cancer.
Serena Nik-Zainal, MD, discusses study findings that could change the way treatment strategies for subgroups of patients with triple-negative breast cancer are evaluated.
A new study looked at the characteristics of diagnosed breast cancer cases in San Francisco.
Several clinicopathologic features of HER2-positive breast cancer patients were found to be associated with response to neoadjuvant therapy in a new study.
CancerNetwork® spoke with Dr. Peter Schmid about the KEYNOTE-522 trial.
Multigene testing for all woman diagnosed with breast cancer can be “extremely cost-effective.”
CancerNetwork® spoke with Dr. William Wood on the clinical risk of chemotherapy in early breast cancer.
A 21-gene assay is effective in guiding the use of adjuvant chemotherapy in patients with early breast cancer.